Knockdown of Skp2 is more effective in increasing cisplatin cytotoxicity in cisplatin-resistant cells, suggesting Skp2 is likely to be a more promising target in treating cisplatin-resistant tumor cells24. Here, SKP2 is linked to neoplasm.